Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major technology-transfer agreement with Eli Lilly.
Search results for "Hanmi Pharmaceutical"
South Korean Biotechs Race to Conquer the Untapped Global MASH Market
Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
Hanmi Pharm Revives 'LAPSCOVERY' Momentum with $1.26B Eli Lilly Licensing Deal
Hanmi Pharmaceutical has licensed its novel drug candidate sonefpeglutide to global pharmaceutical giant Eli Lilly and...
Hanmi Pharmaceutical, CEO Park Jae-hyun Steps Down: Hwang Sang-yeon Appointed as New CEO Candidate
Hanmi Science is replacing CEO Park Jae-hyun of its subsidiary Hanmi Pharmaceutical and forming a new board of...
Hanmi’s 'Amoprel' Makes Global Waves: World’s First Ultra-Low Triple Hypertension Drug Lands in JACC
The Phase 3 clinical trial results for Hanmi Pharmaceutical’s Amoprel—the world’s first ultra-low-dose triple...
117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years
A review of 25 major South Korean pharmaceutical and biotechnology companies revealed 117 recognized industrial...
Fueling the Future of Biohealth: InterBiz Forum Opens in Jeju With a Record 1,500 Tech Deals
The 24th InterBiz Bio Partnering & Investment Forum 2026, a premier biohealth technology deal-making event, opened...
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...